After serving as the interim leader for almost two years, William Farrar will become CEO of The Ohio State University Arthur G. James Cancer Hospital and Richard J. Solove Research Institute (The James), pending approval by The Ohio State University Board of Trustees.
In two back-to-back, all-day meetings, the FDA Oncologic Drugs Advisory Committee considered four thorny applications that the agency appeared to have been saving up as a result of the pause in activity that followed President Trump’s return to office.
